Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 242, pseudogene" (RNU6-242P) is annotated as a pseudogene of the U6 small nuclear RNA (snRNA) family. U6 snRNA itself is a crucial non-coding RNA component of the spliceosome, involved in pre-mRNA splicing[2][3]. However, pseudogenes are typically non-functional genomic sequences that resemble active genes but do not produce functional RNA or protein products. There is no evidence that this pseudogene encodes any active molecule, nor is it considered a traditional drug or therapeutic target. U6 snRNA and related genes are well described, but individual pseudogenes such as RNU6-242P are not functionally characterized and are not known to participate in biological functions or disease, nor do they have associated drugs or biomarker roles in current literature[2][3]. If you intended to refer to the canonical, functional U6 snRNA (not a pseudogene), please clarify, as U6 snRNA itself is essential for spliceosome activity in eukaryotic RNA splicing[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 242, pseudogene (RNU6-242P).